You are here

GSK aims to file up to 20 new drugs for approval by 2020

GlaxoQuarters031115.jpg
GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.

[LONDON] GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.

Britain's biggest drugmaker is trying to boost low investor expectations for its product pipeline by hosting its first research and development day in more than a decade.

The company highlighted advanced and early-stage projects in respiratory medicine, immunology, oncology, vaccines, HIV and other infections, and rare diseases.

REUTERS